宏觀試驗

2023年7月13日

宏觀試驗-一個新的精密研究臨床平台最近推出了將臨床試驗。和公司的創始人孵化與宏觀試驗啟動工作室,一個風險工作室交叉,共同創造公司的醫療保健、生命科學和技術。作為啟動的一部分,該公司還宣布600萬美元的種子資金持續的產品開發,擴大臨床試驗基礎設施跨地域和治療領域,並擴展其研究執行和數據生成飛輪,因為它滿足了迫切的市場需求。一輪融資是由MBX資本,包括參與發起企業,全球健康風險,改變健康和村莊。2021年,有84年破紀錄的新藥推出,另一個20000年的發展。盡管2120億美元用於研發,成功率達到5%的紀錄低點。這些高失敗率繼續抬高為市場帶來一種新藥的費用:現在成本約27億美元商業化與70%的高價值的治療花費歸因於進行臨床試驗。但80%的這些試驗不符合招生目標和挑戰卻沒有結束。甚至被FDA批準的藥物後,藥物可能仍然未能實現其治療目標在更廣泛的人群,經常由於有色人種的重要話語權缺失,女性和老年人進行的臨床試驗。正麵和宏觀解決這些問題將嚴格測試,拯救生命的藥物市場比以往更快、更便宜。 Through its digitally powered infrastructure, Macro works closely with pharmaceutical companies, CROs, physicians, and health systems to design, plan, and execute clinical trials for high-value therapeutics with increased research velocity. And through the aggregation and synthesis of proprietary real-world evidence (RWE), Macro generates an immensely valuable longitudinal patient record. Powered by a distributed “hub-and-spoke” model, the company has conducted trials in all research settings – from in-person to decentralized. And Macro’s turnkey platform empowers physician groups and independent clinicians to participate in groundbreaking research via workflow-native efficiency tools, clinical research personnel, a network of logistic partners, and digital infrastructure for real-time data collection and management. And by enabling patient recruitment at the site of care, Macro and its network of principal investigators lower the barrier to entry in clinical research by meeting patients where they are, driving a track record of equitable enrollment that reflects the diversity of the impacted population. From even the earliest trials, Macro has proven that it truly unlocks increased diversity for results that map to real-world patient demographics for greater post-market success. For example, based on a recent representative study Macro enrolled more than 75% female trial participants compared to an industry standard of 41%; showed age disparity between trial participants and patients of less than one year, compared to the typical 7-10 years; and 46% of Macro’s trial participants were Hispanic-identifying compared to the typical 6% average Hispanic representation observed in clinical research. KEY QUOTES: “High-value therapeutics are the largest and fastest growing segment of pharmaceutical pipelines, but because clinical trials are fundamentally broken, many life-saving drugs will never make it to market. And those that do will cost far more than they should. Macro’s patient centric model and generation of net-new data will improve the R&D landscape so that safer, better drugs will become more accessible.” — Zeshan Muhammedi, Managing Partner of MBX Capital “We are living through a golden age of therapeutics, but there are glaring gaps that make it challenging for breakthrough research to be brought to market. Macro Trials is purpose-built to address these gaps with our patient-focused, end-to-end clinical research platform. Harnessing the latest technology advances, we believe we can amplify therapeutic value from one patient to millions, ultimately transforming care.” — Iana Dimkova, CEO of Macro Trials Trending on Pulse 2.0